INTERNATIONAL JOURNAL OF PHARMA PROFESSIONAL'S RESEARCH

Innovations in Molecular Docking: A Detailed Analysis of Methodological Developments and Their Applications in Drug Discovery

Yatindra Kumar, *Sachin Kumar
Dept of Pharmacy, GSVM Medical College Kanpur UP

ABSTRACT

An in-depth analysis of recent developments in molecular docking is presented in this review. Particular attention is paid to the influence that these methodological breakthroughs have had on the process of drug discovery. Our investigation focuses on the development of docking algorithms, which includes the enhancement of scoring functions, sampling strategies, and flexibility modeling systems. In this article, we address the incorporation of machine learning and artificial intelligence into docking procedures, focusing on the role that these technologies play in improving the accuracy of predictions and the efficiency of computation processes. When it comes to protein flexibility and dynamics, we investigate the evolution of ensemble-based approaches and their capacity to take these factors into account. The paper also discusses recent developments in fragment-based docking and how it might be applied to optimizing leads. To develop docking techniques that provide a more precise depiction of molecular interactions, we investigate the possibility of including quantum mechanical calculations. It discusses how cloud-based platforms and high-performance computer solutions have become increasingly popular for large-scale virtual screening. In addition to this, we assess the development of techniques for protein-protein and protein-peptide docking methodologies. This review investigates how these developments have been utilized to work with difficult therapeutic targets, such as proteins that are intrinsically disordered and allosteric sites. In conclusion, we will talk about the incorporation of docking with many other computational and experimental methods in drug development pipelines. This will provide a forward-looking view of the potential and future directions of the discipline, as well as its potential impact on pharmaceutical research.

Keywords: *Molecular docking, Drug discovery, Scoring functions, Machine learning, Protein flexibility, Fragment-based docking, Protein-protein interactions, Computational chemistry*

Corresponding Author-
Sachin Kumar
Email id: drskmededu@gmail.com
Dept of Pharmacy, GSVM Medical College Kanpur UP

Volume 15, Issue 3, 2024, Received: 15 May 2024, **Accepted:** 10 June 2024, **Published:** 30 July 2024,
DOI: 10.69580/IJPPR.15.3.2024.52-67

1. Introduction

1.1 Molecular Docking

Molecular docking is a computational technique used to predict the preferred orientation of one molecule, typically a small molecule like a drug or ligand, when bound to a second molecule, such as a protein or nucleic acid, to form a stable complex. This technique plays a crucial role in drug discovery and development by modeling the interaction between a drug candidate and its biological target. The primary goal of molecular docking is to identify the ligand's optimal binding configuration to the target molecule's active site, which helps predict the binding affinity and, consequently, the potential efficacy of the drug candidate.[1] The process involves two main components: a search algorithm and a scoring function. The search algorithm explores possible orientations and conformations of the ligand within the binding site of the target molecule, using various methods such as genetic algorithms, Monte Carlo simulations, and particle swarm optimization to navigate the vast conformational space. Once potential binding poses are identified, the scoring function evaluates them based on predicted binding energy or other relevant criteria, ranking them to highlight the most likely binding configuration that will form a stable complex with the target molecule. Molecular docking is instrumental in understanding molecular interactions at the atomic level, guiding the design of more effective and selective therapeutic agents, and reducing the need for extensive experimental trials in the early stages of drug development.[2,3]

1.2 Importance in Drug Discovery

Molecular docking is immensely important in drug discovery as it significantly accelerates identifying and optimizing potential drug candidates. By simulating the interaction between drug molecules and their biological targets, molecular docking helps researchers understand how drugs bind to their targets at the atomic level. This insight is crucial for predicting the efficacy and specificity of drug candidates, thereby enabling the design of more effective and selective therapeutic agents.[4] The technique also helps in the identification of lead compounds by screening

vast libraries of molecules to find those with the highest binding affinity to the target, reducing the time and cost associated with experimental testing. Furthermore, molecular docking aids in the optimization of lead compounds by predicting the effects of structural modifications on binding affinity and activity, guiding the rational design of drugs with improved properties. Overall, molecular docking is a valuable tool that enhances the efficiency of drug discovery, minimizes the need for extensive laboratory experiments, and accelerates the development of new and more effective therapies.[5,6]

The article "Innovations in Molecular Docking: A Detailed Analysis of Methodological Developments and Their Applications in Drug Discovery" reviews recent advancements in molecular docking techniques, highlighting their enhanced accuracy and efficiency in drug discovery. It explores methodological innovations, such as machine learning integration and hybrid approaches, and their practical applications in identifying and optimizing drug candidates.

2. Historical Background

Early methods and developments in molecular docking were pivotal in revolutionizing computational chemistry and advancing drug discovery. Originating in the late 20th century, these methods initially relied on geometric and empirical approaches to predict how small molecules bind to protein targets. Geometric methods involved fitting ligands into receptor binding sites based on shape complementarity and electrostatic interactions. Empirical scoring functions were introduced to estimate binding affinity, although early versions struggled with accurately accounting for receptor flexibility and predicting precise binding conformations.[7]

The 1990s marked a significant turning point with the refinement of scoring functions. This era saw the integration of more sophisticated energy terms derived from empirical potentials, force fields, and knowledge-based potentials derived from structural databases. These advancements improved the accuracy of predicting binding affinities and enabled more realistic simulations of ligand-receptor interactions.[8]

Algorithmic developments were also crucial during this period. Lamarckian genetic algorithms, Monte Carlo methods, and stochastic search techniques emerged as powerful tools for exploring the vast conformational space of ligands and optimizing docking poses. These algorithms allowed researchers to overcome some of the challenges posed by receptor flexibility and conformational variability, enhancing the reliability of docking predictions.[9]

Despite their limitations, early docking methods played a crucial role in early-stage drug discovery. They facilitated the virtual screening of compound libraries, enabling researchers to prioritize potential drug candidates for further experimental validation. This foundational work laid the groundwork for subsequent innovations in molecular docking, which now incorporate advanced computational techniques such as machine learning, quantum mechanics, and enhanced sampling

methods. These modern approaches continue to push the boundaries of drug discovery, offering more accurate and efficient tools for designing new therapeutic agents.[10]

2.1 Key milestones in molecular docking

Molecular docking is a pivotal computational technique used in drug discovery and molecular biology to predict how molecules, such as small molecules or drugs, interact with target proteins. Here are some key milestones in the development of molecular docking:

2.1.1 Early Developments (1970s-1980s):

The concept of molecular docking emerged from early computational simulations of molecular interactions, where initial attempts primarily focused on achieving geometric complementarity between ligands (small molecules) and receptors (target proteins). Researchers aimed to predict how these molecules fit together in three-dimensional space, exploring how ligands could bind within the binding sites of target proteins based on their shapes and surface properties. These foundational efforts laid the groundwork for developing algorithms and scoring functions that could more accurately predict and simulate molecular interactions, advancing the field of computational biology and drug discovery.[11]

2.1.2 Development of Algorithms and Scoring Functions (1990s):

The 1990s marked a significant era of advancement in molecular docking, with notable progress in algorithms and scoring functions. During this period, docking algorithms underwent refinement, incorporating Fast Fourier Transform-based methods to enhance computational efficiency. These techniques allowed for quicker calculations of potential ligand-protein interactions, facilitating larger-scale virtual screenings and more detailed analyses of molecular binding.

Scoring functions evolved substantially in the 1990s. They became more sophisticated, aiming to assess binding affinities and predict ligand-protein interactions with greater accuracy. These advancements were crucial as they enabled researchers to not only identify potential binding poses but also to prioritize compounds based on their likelihood of forming stable complexes with target proteins. Overall, the developments in algorithms and scoring functions during the 1990s laid a robust foundation for the continued evolution and application of molecular docking in drug discovery and computational biology.[12]

2.1.3 Introduction of Flexible Docking (2000s):

Flexibility in both ligands and protein receptors became a critical focus in the evolution of molecular docking, particularly advancing in the early 2000s. This emphasis allowed for more

realistic simulations of molecular interactions by accommodating the dynamic nature of both ligands and protein receptors. Flexible docking methods, such as induced-fit docking, emerged to address the conformational changes that proteins undergo upon binding with ligands. Unlike earlier rigid docking approaches, induced-fit docking accounts for the flexibility of the protein structure, adjusting its conformation to better fit the bound ligand. These advancements significantly improved the accuracy and reliability of docking predictions, reflecting a more comprehensive understanding of molecular interactions and enhancing the effectiveness of virtual screening in drug discovery and molecular biology research.[13]

2.1.4 Integration with Structural Biology and Bioinformatics (2010s):

The integration of molecular docking with structural biology techniques such as X-ray crystallography and NMR spectroscopy has been pivotal in enhancing the accuracy of predicted binding modes. These experimental methods provide detailed insights into the three-dimensional structures of proteins and their complexes with ligands, offering valuable data to validate and refine docking predictions. By aligning computational models with experimental structures, researchers can better understand the molecular interactions governing ligand binding, improving the reliability of virtual screening and lead optimization in drug discovery.[14]

Bioinformatics tools and databases have played a crucial role in supporting docking studies. They provide extensive resources for accessing and analyzing biological data, including protein structures, ligand libraries, and interaction databases. These resources facilitate large-scale virtual screening efforts, allowing researchers to screen vast compound libraries against target proteins efficiently. As a result, bioinformatics-driven approaches have accelerated the pace of drug discovery and enabled the exploration of new therapeutic candidates with potential applications across various fields of medicine and biotechnology.[15]

2.1.5 Advancements in Machine Learning and AI (Recent Years):

Recent advancements in molecular docking have seen a significant integration of machine learning (ML) and artificial intelligence (AI) techniques, marking a paradigm shift in computational biology and drug discovery. ML and AI are now applied to optimize docking processes by enhancing scoring functions, which traditionally evaluate the likelihood and strength of protein-ligand interactions. These advanced algorithms can learn from vast datasets of known ligand-protein complexes, identifying patterns and correlations that improve the accuracy of predicting binding affinities and identifying potential drug candidates.[16]

ML and AI accelerate virtual screening processes by automating and streamlining the identification of promising compounds from large libraries. By leveraging computational power

and advanced algorithms, researchers can conduct virtual screenings more efficiently, narrowing down candidates that are more likely to exhibit desired pharmacological properties.

The integration of ML and AI into molecular docking has not only enhanced the precision and efficiency of predicting protein-ligand interactions but also expanded the scope of drug discovery by enabling more comprehensive and rapid exploration of chemical space. These technologies continue to drive innovation in computational biology, offering promising avenues for discovering novel therapeutics and understanding complex biological systems.[17]

2.1.6 Application in Drug Discovery and Personalized Medicine:

Molecular docking has become a cornerstone in contemporary drug discovery and development, essential for rational drug design, lead optimization, and virtual screening of compound libraries. It plays a pivotal role in predicting and optimizing how potential drug molecules interact with target proteins, aiding in the identification and refinement of lead compounds with optimal binding characteristics. This computational technique accelerates the drug development process by efficiently screening large libraries of compounds to identify promising candidates for further experimental testing. Beyond discovery, molecular docking enhances our understanding of drug-target interactions, shedding light on mechanisms of action and guiding the design of more effective and personalized therapeutic strategies. By integrating computational simulations with experimental data, researchers can tailor treatments based on individual genetic and molecular profiles, advancing personalized medicine approaches. Overall, molecular docking continues to drive innovation in pharmaceutical research, offering powerful tools to discover, optimize, and understand the mechanisms of new therapeutic agents.[18,19]

Table 1: Evolution of techniques over time

Time-Period	Key Developments
1970s-1980s	• Conceptual beginnings of molecular docking • Focus on geometric complementarity between ligands and proteins [20]
1990s	• Introduction of Fast Fourier Transform-based methods for efficiency • Development of initial scoring functions for binding affinities [21]
2000s	• Integration of flexibility in ligands and protein receptors • Emergence of flexible docking methods like induced-fit docking • Enhanced integration with structural biology techniques [22]

2010s	• Advancements in machine learning and AI for optimizing scoring functions • Acceleration of virtual screening processes [23]
Present	• Widely used in rational drug design and lead optimization • Crucial role in understanding drug-target interactions • Exploration of personalized medicine approaches [24]

3. Methodological Developments



Figure 1: Methodological Developments

3.1 Lock-and-Key Model

The lock-and-key model, proposed by Emil Fischer in 1894, suggests that enzymes and substrates have complementary geometric shapes that fit exactly, like a lock and key. This model explained experimental observations at the time and remained the accepted theory for 60 years.[25]

3.2 Induced Fit Theory

In the late 1950s, Daniel Koshland proposed the induced fit theory, which refined the lock-and-key model. This theory states that the enzyme's active site is flexible and can change shape upon substrate binding to optimize the interaction. The induced fit model helps explain non-competitive inhibition, where a molecule that binds away from the active site can still interfere with substrate binding.[26]

3.3 Computational Advances

Over recent decades, advances in computing power and software design have supported progress in understanding enzyme structure and action. Computational techniques like algorithms, machine learning, AI integration, and quantum mechanics/molecular mechanics (QM/MM) methods have been applied to predict enzyme structures, design drug molecules, and analyze enzyme flexibility.[27]

3.4 Hybrid Methods

Researchers have combined different computational techniques to study enzyme catalysis. Hybrid methods leverage the strengths of various approaches while addressing their limitations. However, developing and applying these methods can be challenging due to the complexity of enzyme systems and the need for interdisciplinary collaboration.[28]

4. Technological Innovations in Drug Discovery and Development

4.1 High-Performance Computing (HPC)

High-Performance Computing (HPC) refers to using powerful computers and parallel processing techniques to solve complex computational problems quickly and efficiently. In the context of drug discovery, HPC enables the simulation of molecular interactions at an unprecedented scale and speed. It allows researchers to analyze large datasets, run complex simulations, and perform detailed modeling tasks that would be otherwise impossible with traditional computing resources.[29]

4.1.1 Cloud Computing

Cloud computing provides on-demand access to computing resources over the internet. This model offers scalability, flexibility, and cost-effectiveness, as it eliminates the need for significant upfront investment in hardware. In drug discovery, cloud computing enables collaborative research, where scientists from different locations can share data and computational resources. It also facilitates the storage and analysis of large datasets, making it easier to manage and process high-throughput screening results and other complex data.[30]

4.1.2 GPU Acceleration

Graphics Processing Units (GPUs) are specialized hardware designed to accelerate computationally intensive tasks by parallelizing operations. In drug discovery, GPU acceleration is particularly beneficial for tasks such as molecular docking, molecular dynamics simulations, and machine learning applications. Researchers can significantly reduce the time required for these computations by leveraging GPUs, enabling faster and more efficient drug discovery processes.[31]

4.2 Virtual Screening

Virtual screening is a computational technique used to identify potential drug candidates by evaluating a large library of compounds against a biological target.[32]

4.2.1 Structure-based Virtual Screening

Structure-based virtual screening involves using the 3D structure of a target protein to identify potential ligands that can bind to it. This approach typically involves docking simulations, where candidate molecules are computationally "fitted" into the binding site of the target protein to predict their binding affinity and activity.[33]

4.2.2 Ligand-based Virtual Screening

Ligand-based virtual screening relies on the knowledge of known active compounds to identify new candidates. This method uses the chemical and physical properties of known ligands to develop models that can predict the activity of new compounds. Techniques such as quantitative structure-activity relationship (QSAR) modeling and similarity searching are commonly used in ligand-based screening.[34]

4.3 Molecular Dynamics (MD) Simulations

Molecular dynamics (MD) simulations involve computationally modeling the physical movements of atoms and molecules over time. This technique provides detailed insights into the dynamic behavior of biomolecular systems, such as protein-ligand interactions, conformational changes, and stability.

4.3.1 Role of MD in Docking

MD simulations play a crucial role in refining docking results by accounting for the flexibility and dynamic nature of proteins and ligands. While traditional docking provides a static snapshot of binding interactions, MD simulations can explore the conformational space of the protein-ligand complex, providing a more accurate prediction of binding affinities and identifying potential binding modes that might be missed in static docking.[35]

4.3.2 Enhanced Sampling Methods

Enhanced sampling methods are advanced MD techniques designed to overcome the limitations of traditional MD simulations, such as the inability to efficiently explore large conformational spaces. These methods, including metadynamics, umbrella sampling, and replica exchange MD, accelerate the exploration of conformational states, enabling the study of rare events and transitions that are critical for understanding complex biological processes and improving the accuracy of drug discovery predictions.[36]

5 Application Examples of Molecular Docking for Drug Discovery

It has been shown that molecular docking is the technique that has been used the most. It is not a stand-alone technique; rather, it is typically integrated into a workflow that includes a variety of in-silico and experimental techniques. Although the primary application of this technique is structure-based virtual screening for the identification of new active compounds directed toward a specific target protein, which it has produced several success stories, it is typically not a stand-alone technique. Several research organizations are concentrating their efforts on assessing the effectiveness of a variety of docking algorithms or on enhancing the scoring functions after the experimental testing has already been completed. When it comes to selecting the approach for a specific target system, such efforts could provide valuable insight. It is also possible that docking, in conjunction with other computational methods and experimental data, might be utilized in the process of studying drug metabolism to acquire some helpful information from the cytochrome P450 system. Examples of docking applications that have been effective are described in the following paragraphs. [37]



Figure 2: Applications of Molecular Docking

The bacterial enzyme known as DNA gyrase is being investigated as a potential antibacterial target since it is responsible for the introduction of negative supercoils into bacterial DNA and the unwinding of DNA. HTS couldn't discover any new DNA gyrase inhibitors. The de novo design approach was utilized by Boehm et al. for this enzyme, and they were able to successfully obtain numerous novel inhibitors. To begin, the three-dimensional complex structures of DNA gyrase with known inhibitors, ciprofloxacin and novobiocin, were meticulously examined to obtain a similar binding pattern. This pattern was found to be one in which both inhibitors supply one hydrogen bond to Asp73 and accept one hydrogen bond from a conserved water molecule. Additionally, to have a lipophilic interaction with the receptor, the molecule must contain a few lipophilic fragments. As a result of this information, LUDI and CATALYST were utilized to search the Available Chemicals Directory (ACD) and a portion of the Roche compound inventory (RIC), respectively, and they gathered approximately 600 compounds. Moreover, close analogs of these compounds were taken into consideration; hence, a total of three thousand compounds were subjected to additional testing employing biased screening. As a consequence of this, 150 hits were chosen and grouped into 14 classes, only seven of these classes were found to be genuine and unique inhibitors. The subsequent hit optimization process was heavily dependent on the knowledge of the three-dimensional structures of the binding site, which ultimately resulted in the production of many very effective DNA gyrase inhibitors.[38]

6 Challenges in Molecular Docking

Certain basic challenges in docking and scoring are discussed under the following headings.

6.1 Ligand chemistry: Since the recognition of ligands by any biomolecule is dependent on three-dimensional orientation and electrostatic contact, the production of the ligand has a significant impact on the docking outcomes. This provides more evidence that the conformation of the ligand, in addition to the synthesis of the ligand, is of critical significance. Earlier, while maintaining approximate pKa values, the structure was most likely adjusted by deleting or adding hydrogens; however, the tautomeric and protomeric states of the molecules that were to be docked caused a significant disparity. This was the case even though the structure was optimized. because the vast majority of databases store molecules in their neutral states, even though during physiological settings, molecules are ionized. They must therefore be ionized before docking, as this is a requirement. However, the typical ionization can be easily accomplished in a variety of application packages. Regarding the matter of tautomers, the difficulty that must be addressed is still the question of which tautomer one ought to employ, or whether one ought to use all of the tautomers that are available.[39]

6.2 Receptor flexibility: This is a major challenge in docking i.e., handling of flexible protein. A biomolecule/protein adopts different conformations depending on the ligand to which it binds. This confirms that docking done with a rigid receptor will give a single conformation of the receptor. However, when the docking is done with flexible receptors, the ligands may require many

receptor conformations to bind. In molecular docking studies, usually, the most neglected aspect is the different conformational states of proteins. Since protein flexibility is important as it accounts for better affinity to be achieved between a given drug and target. Another aspect of target flexibility is active site water molecules. Water molecules must be rectified to avoid using artifact waters in the docking process. [40]

6.3 Scoring function: Another challenge in docking is an imperfection in the scoring function. Just like the search algorithm has the potential to give optimum conformation, the scoring function should also be able to differentiate true binding modes from all the other parallel modes. A potential scoring function would be computationally economical and unfavorable for analyzing several binding modes. When there is accuracy, scoring functions make some suggestions to evaluate ligand affinity. The physical phenomenon i.e., entropy and electrostatic interactions are disregarded in scoring schemes. Hence the lack of a suitable scoring function, both in terms of accuracy and speed, is the main congestion in molecular docking programming.[41]

7. Limitations Of Molecular Docking

Molecular docking is a widely used computational method in molecular modeling and drug discovery, but it has several limitations. Traditional docking methods often assume the rigidity of proteins, which can inaccurately represent the conformational changes proteins undergo upon ligand binding, especially in induced-fit systems. The reliability of scoring functions used to predict binding affinity between ligands and target proteins is limited, particularly when terms in different scoring functions are significantly correlated, affecting affinity prediction accuracy.[42] Additionally, many scoring functions inadequately treat the solvation effect, impacting binding affinity predictions, although physics-based methods like MM-PB/SA and MM-GB/SA have been developed to address this. Progress in drug discovery through molecular docking is also hindered by an incomplete understanding of the underlying molecular processes of targeted diseases. Most docking tools provide high flexibility to ligands while keeping proteins relatively fixed, potentially missing dynamic interactions and affecting results. Furthermore, despite academic success, real-life applications of molecular docking are limited, with challenges in identifying true ligands among a set of molecules and determining the correct ligand conformation within the binding pocket.[43]

8. Conclusion

The methodological advances in molecular docking and their applications in drug discovery have been thoroughly examined in this review paper, which has provided a detailed study of these developments. Based on the findings of the study, it is clear that molecular docking has developed into an indispensable instrument in this area. It has made significant strides in terms of improving the accuracy and reliability of binding affinity predictions. These advancements include the incorporation of protein flexibility, improved scoring functions, and enhanced treatment of solvation effects. Researchers have been able to investigate a greater variety of chemicals as a

result of these methodological advancements, which has led to the identification and optimization of prospective therapeutic candidates. Numerous successful case studies highlight the practical uses of molecular docking in drug development. These case studies indicate the role that molecular docking plays in accelerating the process of drug discovery and lowering the amount of time and resources that are required for preclinical research. However, despite these advancements, there are still obstacles to be faced, particularly in the exact handling of solvation effects and the flexibility of ligands and proteins, both of which are areas that are continuously being researched and improved. It is anticipated that the continued development of these areas will lead to improvements in the precision and dependability of molecular docking, which will ultimately result in applications that are even more useful in the field of drug discovery. It is hoped that future methodological innovations will solve the limits of molecular docking and unlock its full potential for the discovery of novel medications. The advancements in molecular docking have transformed the process of drug discovery. The continuing incorporation of molecular docking into the drug discovery pipeline offers a great deal of potential for the future. This will, in the end, lead to the creation of medicines that are more effective and precisely targeted for a wide variety of ailments.

9. Conflict of interest

The authors have no conflict of interest.

10. Acknowledgement

Authors are highly thankful to their Universities/Colleges for providing library facilities for the literature survey.

References

1. Kukol A. *Molecular Modeling of Proteins*. Vol 443.; 2008.
2. Agarwal S, Mehrotra R. An overview of Molecular Docking. *JSM Chem*. 2016;4(2):1024.
3. Dar AM, Mir S. Molecular Docking: Approaches, Types, Applications and Basic Challenges. *J Anal Bioanal Tech*. 2017;08(02). doi:10.4172/2155-9872.1000356
4. Pagadala NS, Syed K, Tuszynski J. Software for molecular docking: a review. *Biophys Rev*. 2017;9(2):91-102. doi:10.1007/s12551-016-0247-1
5. Adelusi TI, Oyedele AQK, Boyenle ID, et al. Molecular modeling in drug discovery. *Inform Med Unlocked*. 2022;29. doi:10.1016/j.imu.2022.100880
6. Pinzi L, Rastelli G. Molecular docking: Shifting paradigms in drug discovery. *Int J Mol Sci*. 2019;20(18). doi:10.3390/ijms20184331
7. García-Godoy MJ, López-Camacho E, García-Nieto J, Del Ser J, Nebro AJ, Aldana-Montes JF. Bio-inspired optimization for the molecular docking problem: State of the art, recent results and perspectives. *Applied Soft Computing Journal*. 2019;79:30-45. doi:10.1016/j.asoc.2019.03.044
8. Chen G, Seukep AJ, Guo M. Recent Advances in Molecular Docking for the Research and Discovery of Potential Marine Drugs. *Mar Drugs*. 2020;18(11). doi:10.3390/md18110545

9. Azam SS, Abbasi SW. Molecular docking studies for the identification of novel melatoninergic inhibitors for acetylserotonin-O-methyltransferase using different docking routines. *Theor Biol Med Model*. 2013;10(1). doi:10.1186/1742-4682-10-63

10. Boittier ED, Tang YY, Buckley ME, Schuurs ZP, Richard DJ, Gandhi NS. Assessing molecular docking tools to guide targeted drug discovery of cd38 inhibitors. *Int J Mol Sci*. 2020;21(15):1-19. doi:10.3390/ijms21155183

11. Torres PHM, Sodero ACR, Jofily P, Silva-Jr FP. Key topics in molecular docking for drug design. *Int J Mol Sci*. 2019;20(18). doi:10.3390/ijms20184574

12. Singh S, Bani Baker Q, Singh DB. Molecular docking and molecular dynamics simulation. In: *Bioinformatics: Methods and Applications*. Elsevier; 2021:291-304. doi:10.1016/B978-0-323-89775-4.00014-6

13. Stanzione F, Giangreco I, Cole JC. *Chapter Four-Use of Molecular Docking Computational Tools in Drug Discovery*.; 2021. https://doi.org/./bs.pmch.

14. Agu PC, Afiukwa CA, Orji OU, et al. Molecular docking as a tool for the discovery of molecular targets of nutraceuticals in disease management. *Sci Rep*. 2023;13(1). doi:10.1038/s41598-023-40160-2

15. Ferreira LG, Dos Santos RN, Oliva G, Andricopulo AD. Molecular docking and structure-based drug design strategies. *Molecules*. 2015;20(7):13384-13421. doi:10.3390/molecules200713384

16. Hameed BMZ, Prerepa G, Patil V, et al. Engineering and clinical use of artificial intelligence (AI) with machine learning and data science advancements: radiology leading the way for future. *Ther Adv Urol*. 2021;13. doi:10.1177/17562872211044880

17. Husnain A, Khawar Hussain H, Muhammad Shahroz H, Ali M, Hayat Y. Revista Española de Documentación Científica Advancements in Health through Artificial Intelligence and Machine Learning: A Focus on Brain Health. Published online 2024.

18. Aguiar C, Camps I. Molecular Docking in Drug Discovery: Techniques, Applications, and Advancements. Published online 2024. doi:10.26434/chemrxiv-2024-gmhtx

19. Podlipnik Č. *from the edited volume Unravelling Molecular Docking-From Theory to Prac Tice [Working Title] 90% Publication Fee Discount Unravelling Molecular Docking-From Theory to Practice*.; 2024. https://www.intechopen.com/online-first/1177924

20. Salmaso V, Moro S. Bridging molecular docking to molecular dynamics in exploring ligand-protein recognition process: An overview. *Front Pharmacol*. 2018;9(AUG). doi:10.3389/fphar.2018.00923

21. Nguyen TH, Zhou HX, Minh DDL. Using the Fast Fourier Transform in Binding Free Energy Calculations. Published online July 27, 2017. doi:10.1002/jcc.25139

22. Feixas F, Lindert S, Sinko W, McCammon JA. Exploring the role of receptor flexibility in structure-based drug discovery. *Biophys Chem*. 2014;186:31-45. doi:10.1016/j.bpc.2013.10.007

23. Singh S, Gupta H, Sharma P, Sahi S. Advances in Artificial Intelligence (AI)-assisted approaches in drug screening. *Artificial Intelligence Chemistry*. 2024;2(1):100039. doi:10.1016/j.aichem.2023.100039

24. Paul D, Sanap G, Shenoy S, Kalyane D, Kalia K, Tekade RK. Artificial intelligence in drug discovery and development. *Drug Discov Today*. 2021;26(1):80-93. doi:10.1016/j.drudis.2020.10.010

25. Tripathi A, Bankaitis VA. *Molecular Docking: From Lock and Key to Combination Lock*.; 2017.

26. Belorkar SA, Jogaiah S. *Protocols and Applications in Enzymology Chapter 1-Enzymes-Past, Present, and Future Get Rights and Content*.; 2022. https://www.sciencedirect.com/science/article/abs/pii/B9780323912686000077

27. Yang ZJ, Shao Q, Jiang Y, et al. Mutexa: A Computational Ecosystem for Intelligent Protein Engineering. *J Chem Theory Comput*. 2023;19(21):7459-7477. doi:10.1021/acs.jctc.3c00602

28. Cao Y, Ge J. Hybrid enzyme catalysts synthesized by a de novo approach for expanding biocatalysis. *Chinese Journal of Catalysis*. 2021;42(10):1625-1633. doi:10.1016/S1872-2067(21)63798-1

29. Lee K, Lee S. Knowledge structure of the application of high-performance computing: A co-word analysis. *Sustainability (Switzerland)*. 2021;13(20). doi:10.3390/su132011249

30. Dueholm Müller S, Rubaek Holm Accenture Jens Søndergaard Accenture S, Dueholm S, Rubaek S, Rubaek Holm S, Søndergaard J. Benefits of Cloud Computing: Literature Review in a Maturity Model Perspective. *Communications of the Association for Information Systems*. 2015;37:42. http://aisel.aisnet.org/cais/vol37/iss1/42

31. Bertil Schmidt & Andreas Hildebrandt. From GPUs to AI and quantum: three waves of acceleration in bioinformatics. Published online 2024.

32. Zhang H, Shen C, Zhang HR, Qi HZ, Hu ML, Luo QQ. Identification of Novel Inhibitors Targeting SGK1 via Ensemble-Based Virtual Screening Method, Biological Evaluation and Molecular Dynamics Simulation. *Int J Mol Sci*. 2022;23(15). doi:10.3390/ijms23158635

33. Gimeno A, Ojeda-Montes MJ, Tomás-Hernández S, et al. The light and dark sides of virtual screening: What is there to know? *Int J Mol Sci*. 2019;20(6). doi:10.3390/ijms20061375

34. Maia EHB, Assis LC, de Oliveira TA, da Silva AM, Taranto AG. Structure-Based Virtual Screening: From Classical to Artificial Intelligence. *Front Chem*. 2020;8. doi:10.3389/fchem.2020.00343

35. Salo-Ahen OMH, Alanko I, Bhadane R, et al. Molecular dynamics simulations in drug discovery and pharmaceutical development. *Processes*. 2021;9(1):1-63. doi:10.3390/pr9010071

36. Hollingsworth SA, Dror RO. Molecular Dynamics Simulation for All. *Neuron*. 2018;99(6):1129-1143. doi:10.1016/j.neuron.2018.08.011

37. Sethi A, Joshi K, Sasikala K, Alvala M. Molecular Docking in Modern Drug Discovery: Principles and Recent Applications. In: *Drug Discovery and Development - New Advances*. IntechOpen; 2020. doi:10.5772/intechopen.85991

38. Muhammed MT, Aki-Yalcin E. Molecular Docking: Principles, Advances, and Its Applications in Drug Discovery. *Lett Drug Des Discov*. 2022;21(3):480-495. doi:10.2174/1570180819666220922103109

39. Saikia S, Bordoloi M. Molecular Docking: Challenges, Advances and its Use in Drug Discovery Perspective. *Curr Drug Targets*. 2018;20(5):501-521. doi:10.2174/1389450119666181022153016

40. Prieto-Martínez FD, Arciniega M, Medina-Franco JL. Acoplamiento Molecular: Avances Recientes y Retos. *TIP Revista Especializada en Ciencias Químico-Biológicas*. 2018;21. doi:10.22201/fesz.23958723e.2018.0.143

41. Ghasemi JB, Abdolmaleki A, Shiri F. Molecular Docking Challenges and Limitations. In: *Pharmaceutical Sciences*. IGI Global; 2016:770-794. doi:10.4018/978-1-5225-1762-7.ch030

42. Gaitonde V, Karmakar P, Trivedi A, Details B. *From The Edited Volume Drug Discovery and Development-New Advances Share Cite* 2024. https://www.intechopen.com/chapters/70982

43. Sahu MK, Nayak AK, Hailemeskel B, Eyupoglu OE. Exploring Recent Updates on Molecular Docking: Types, Method, Application, Limitation & Future Prospects. *International Journal of Pharmaceutical Research and Allied Sciences*. 2024;13(2):24-40. doi:10.51847/Une9jqjUCl